Description
A Randomized, Double-blind, Placebo-controlled, Phase 2a Study With Open-label Extension to Evaluate the Safety and Efficacy of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis
Location: CPMC (San Francisco)
Please contact: ClinicalResearch@sutterhealth.org about study Kezar KZR-616-208 PORTOLA